The FDA on Wednesday approved the world’s first respiratory syncytial virus (RSV) vaccine. The shot, made by GlaxoSmithKline (GSK), will be for adults ages 60 and up. According to NBC News, a late-stage clinical trial showed the one-dose shot “lowered the risk of symptomatic illness by 83% and of severe illness by 94%.” Although the CDC…
This post was created with our nice and easy submission form. Create your post!
Comments
Loading…